Hear from Wim Dokter, PhD, our Chief Scientific Officer, about what he sees as the direction of patient-centered Oncology drug development and how Byondis is uniquely positioned to play a role in the future of precision oncology treatment. bit.ly/40gmj8R

Next week’s World Cancer Day, an opportunity to reflect on the progress that has been made & the significant amount of work needed. We are driven to deliver novel precision medicines for people with cancer. bit.ly/4ifx4QL #WorldCancerDay #UnitedbyUnique

We are joining the broad cancer community to better enable prevention, identification & treatment of cancer & reduce its toll on our society. At Byondis, that means a relentless focus on bringing new, personalized therapies to patients. #WorldCancerDay #UnitedByUnique

We are hiring! Learn more about our open positions in Research, Quality and Downstream Processing and how joining the Byondis team means being part of bringing a new generation of ADCs and mAbs to patients with cancer. bit.ly/4isYySC

Our CEO, Jacques Lemmens, PhD, will be joining other leaders on a panel to discuss “ADCs Done Different” at the Van Lanschot Kempen Life Science Conference on April 2. Learn more: bit.ly/4bGeJtz

Today we announced the appointment of Christoph Korpus, PhD, MBA, as Byondis' CBO. Christoph will play a pivotal role in advancing our pipeline of novel ADCs & mAbs & lead Byondis' business development efforts. Welcome Christoph! bit.ly/4jf4tuX

Hear from Founder & CEO, Jacques Lemmens, PhD, about our strategic goals & how our fully-integrated discovery, development & manufacturing capabilities; pipeline of novel ADCs & mAbs & our drug development expertise will propel our progress. bit.ly/4ie3eeB

Our goal is to efficiently advance our proprietary pipeline of novel ADCs & mAbs and further our earlier stage pipeline. Learn more about how collaboration plays a role in maximizing the potential of our science, pipeline and technology. bit.ly/4jgAuCL

We look forward to joining clinicians, researchers and industry collaborators at the American Association of Clinical Research annual conference later this month. Connect with us here: bit.ly/4jgAuCL #AACR2025

⭐We are hiring! Learn more about our open positions in Compliance, Bioprocessing and Analytical Development and Quality Control and how joining the Byondis team means being part of bringing new therapeutic options to patients with cancer. ➡️careers.byondis.com

Our CEO & Founder, Jacques Lemmens, & Chief Business Officer, Christoph Korpus, will be attending BioEquity Europe in Bruges, Belgium May 12-14th. 👉If you are interested in learning more or would like to connect: [email protected] #BioEquityEurope #OncologyResearch #Oncology

Our internship program offers the chance to work on meaningful projects, gain hands-on lab experience, and learn directly from the Byondis team! 👉Learn more: bit.ly/4maHGCr #OncologyResearch #BiotechInternships

First patient dosed in our Phase 1 dose escalation & expansion trial evaluating safety, pharmacokinetics, pharmacodynamics & efficacy of novel SIRPα-directed mAb BYON4228 alone & in combination with pembrolizumab in advanced or metastatic solid tumors. ➡️bit.ly/3FlA67N

Motivated by our mission to bring new therapies to patients with high unmet need and collaborating with skilled professionals across the Company is why colleagues like Eef Dirksen, chose Byondis. ➡️Learn more: bit.ly/3ECRvbq

⭐️Welcome to our new colleagues! Every day at Byondis, we come to work with an inquisitive spirit & a drive to make things happen. We’re thrilled to have passionate, results-oriented minds joining our mission! #WeAreByondis #MakeHopeReal

Data in Bioanalysis by the EBF demonstrate the surrogate matrix strategy can reduce/eliminate the reliance on animal matrices in preclinical bioanalysis. We are proud of the contributions of our Bioanalytics & DMPK team to this important research. ➡️ bit.ly/4lsOvhp

CBO, Christoph Korpus, PhD, & Senior Director Medicinal & Protein Chemistry, Patrick Beusker, PhD, will be speaking at the 2nd Annual ADC and Novel Conjugates Partnering & Investment Summit. 👉If you would like to connect: [email protected] #ADCInnovation #Byondis

Looking forward to connecting with colleagues at BioCentury Grand Rounds Europe in Cambridge, UK. 👉To connect: [email protected] #BioCenturyGrandRoundsEurope #ADCInnovation #Oncology #AntibodyDrugConjugates #Byondis #OncologyResearch #ClinicalTrials #MakeHopeReal

Byondis participated in the ADC Partnering & Investment Summit 2025 in Boston, where Christoph Korpus, PhD, and Patrick Beusker, PhD, showcased how Byondis is working to solve the toughest challenges in ADC development. #ADCInnovation #Byondis #MakeHopeReal

Bas Kokke, PhD, recently presented "Investigations in virus filter process performance at different positions in the downstream process," a critical contribution to the development of innovative compounds like Byondis' work with (masked) mAbs and ADCs. #BioTalkEU #ADCInnovation